"Dropping" is the wrong framing. Replace "dropping" with "strategic licensing".
Any licensee would likely see market share gain in AML if Zan is validated as FTO/CP in other indications. They'd likely run their own trials to demonstrate it is validated as FTO/CP in AML, as they would still need to take RC110 to approval.
So even through I don't believe the pricing of RC110 would benchmark RC220, by the time pricing is established, it would likely consider RC110 as FTO/CP.
Ann: Bisantrene Shows Broad Anti-Cancer Activity in Cancer Cells, page-204
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.55 |
Change
-0.070(4.32%) |
Mkt cap ! $264.0M | |||
| Open | High | Low | Value | Volume |
| $1.62 | $1.65 | $1.54 | $145.6K | 91.60K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5700 | $1.55 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 296 | 1 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |